Regulatable AAV Expression Vector With a Therapeutic Gene Kill Switch
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery systems for treating ocular disorders lack the ability to modulate transgene expression temporally and quantitatively, and existing cell-specific regulating elements are too large for viral vectors with limited cargo capacities, necessitating improved regulatable expression vectors for precise therapeutic control.
Innovation Solution
Development of adeno-associated virus (AAV) expression vectors with a kill switch comprising site-specific recombination sequences and regulatable promoters, allowing for precise control of therapeutic molecule expression through regulator compounds, enabling non-invasive regulation via topical administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cell-specific regulating elements are incorporated into viral vectors to control transgene expression, then expression control capability is improved, but the vector size exceeds cargo capacity constraints
Solution Approach 1:
The regulating system is divided into separate functional modules: a compact regulatable promoter (e.g., tetracycline-responsive element) and a separate regulator compound-binding polypeptide encoded by a constitutive promoter. This segmentation allows each component to be optimized independently for size and function, fitting within viral vector cargo limits while maintaining control capability.
Solution Approach 2:
A small molecule regulator compound (e.g., tetracycline, doxycycline) is introduced as an intermediary to mediate between the external environment and the gene expression system. The regulator compound binds to the polypeptide to modulate promoter activity, enabling indirect control of transgene expression without requiring large regulatory sequences within the vector.
2Manufacturing precision
If regulatable promoters are used to control therapeutic molecule expression, then temporal and quantitative control is improved, but the system complexity increases
Solution Approach 1:
The system merges a regulatable promoter controlling the therapeutic molecule with a constitutive promoter controlling the regulator compound-binding polypeptide into a single expression vector. This integration allows both control elements to function together in a unified system, simplifying delivery while maintaining precise temporal and quantitative expression control through regulator compound administration.
Solution Approach 2:
The system employs self-regulating mechanisms where the regulator compound-binding polypeptide automatically responds to the presence or absence of the regulator compound by modulating promoter activity. This self-service approach eliminates the need for complex external control systems, as the biological system itself performs the regulation in response to simple chemical cues.
3Productivity
If invasive administration methods are used for gene delivery, then delivery efficiency is improved, but patient comfort and safety deteriorate
Solution Approach 1:
The system transitions from static gene delivery to dynamic, reversible control of gene expression. Once the vector is delivered, expression levels can be dynamically adjusted up or down through administration or withdrawal of the regulator compound. This dynamic control allows optimization of delivery efficiency while minimizing harmful effects by reducing expression when therapeutic benefit is no longer needed.
Solution Approach 2:
The system enables temporary gene expression that can be discarded (turned off) when no longer needed, and potentially recovered (turned back on) if required. The regulator compound acts as a switch that can be added or removed to control expression, allowing the system to discard unwanted expression effects without permanent genetic modification, thereby improving safety while maintaining delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV expression vectors provide precise control over therapeutic molecule expression, effectively treating ocular disorders and inflammatory conditions by silencing or activating gene expression as needed, reducing the need for invasive administration methods.
Implementation Method 1
activation of the kill switch by recombination between the first site-specific recombination sequence and the second site-specific recombination sequence silences expression of the nucleic acid encoding the therapeutic molecule from the vector
Implementation Method 2
a constitutive promoter operably linked to a nucleic acid sequence encoding a regulator compound-binding polypeptide which is capable of binding a regulator compound, wherein upon binding the regulator compound, the regulator compound-binding polypeptide regulates expression of the therapeutic molecule
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to regulatable expression vectors for systematically controlling and silencing expression of a therapeutic molecule and uses thereof, e.g. treating ocular disorders such as choroidal neovascularisation.